MENU

News | CellFree Sciences

header jp

header en

News

We in collaboration with Ehime University have developed a new technology to conduct a genome wide evaluation of the specificity of antibodies that can bind to human proteins.

Category: Press releases Created: Thursday, 19 December 2019

The groups from CellFree Sciences Co., Ltd. (Ryo Morishita, R&D manager)  and  Proteo-Science Center, Ehime University (Professor Tatsuya Sawasaki) have successfully developed a new technology that identifies proteins for binding to target antibodies. Using about 20,000 human proteins this technology is best suited for veriflying the specificity of antibodies against human proteins.

  

The new technology utilizes a protein bead array technology developed by CellFree Sciences Co., Ltd. named “CF-PA2Vtech”. The potential of the new method was demonstrated by verifying the specific binding of a commercial anti-PD-1 antibody, where the data demonstrate its binding to several proteins having related linear epitopes.

 

The results from the research were published by Morishita et al. in the December 18, 2019 issue of Scientific Reports:

 

CF-PA2Vtech: a cell-free human protein array technology for antibody validation against human proteins

https://www.nature.com/articles/s41598-019-55785-5

Copyright © CellFree Sciences Co.,Ltd. All Rights Reserved. [login]

We use cookies to ensure you get the best experience. By using our website you agree to our Cookie Policy.